Pan-cancer characterization of C-C motif chemokine ligand 5 (CCL5) identifies its role as biomarker and therapeutic target.

Discov Oncol · 2025 · PMC11880496 · PMID 40035930

Europe PMC DOI

hedged sentence

0.0000

closest p · 0.0× alpha

0.0000

boldest claim

The sentences

highly significantp < 4.19e-11actually significant

These plots demonstrate significant differences in CCL5 expression across these immune subtypes, with p-values from Kruskal–Wallis tests reaching highly significant levels (p < 4.19e-11 for KIRC and p < 1.04e-08 for ESCA).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.